Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cisplatin-Based Chemotherapy followed by Maintenance Avelumab in Upper Tract Urothelial Carcinoma
KCT0010668Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, cisplatin in upper tract urothelial carcinoma (UTUC), sponsored by Merck & Co.. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
avelumabcisplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on KCT0010668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010668.